Gvoke RTU Micro

Gvoke RTU Micro is an investigational **ready-to-use injectable glucagon micro-dose formulation** developed by **Xeris Pharmaceuticals** for prevention of **exercise-induced hypoglycemia** in adults with **type 1 diabetes mellitus** using insulin pumps. It contains **glucagon**, a peptide hormone biologic, formulated with Xeris' **XeriSol** and **XeriJect** technologies to provide room-temperature stability without reconstitution. Pharmacologically, the product acts as a **glucagon receptor agonist**, increasing hepatic glucose output and raising blood glucose concentrations. As described in the provided context, Gvoke RTU Micro was in **Phase 2** development as of 2020, with reported Phase 2 data showing significant prevention of exercise-induced hypoglycemia during prolonged moderate-to-high intensity aerobic exercise.

Brand names

Gvoke RTU Micro

Other names

ready-to-use glucagon micro-doseglucagon micro-dose